Crossmark

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study

Crossref DOI link: https://doi.org/10.1007/s10637-024-01483-7

Published Online: 2024-12-02

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

xu, Manyi

Wang, Yanhua

Wang, Ke

Hao, Yue

Xu, Chunwei

Shi, Lei

Song, Zhengbo
Funding

Funding for this research was provided by:

Natural Science Foundation of Zhejiang Province (Y22H227294)
License Information

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-12-01
More Information

Article History

Accepted: 18 November 2024

First Online: 2 December 2024

Declarations

:

: Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2023–377). Individual consent for this retrospective analysis was waived.

: Not applicable.

: The authors declare no competing interests.

: Individual consent for analysis was waived.

Document is current

Any future updates will be listed below